Key Players
Competitive Landscape
Competition in radiotherapy support nutrition comes down to how well a supplier can stay useful as a patient's eating ability changes. Large medical nutrition groups can offer both oral and enteral products, while smaller companies may focus on one problem such as low-volume protein delivery, dysphagia, altered texture, or digestive tolerance. A broad portfolio helps, but only when the products match what patients can actually consume at each stage of treatment.
Cancer-center buyers also look beyond the nutrition label. A product must be manageable in terms of serving size, texture, preparation, storage, ordering, and patient tolerance. It also needs to remain accessible when the patient moves from hospital care to home. This makes continuity across care settings more valuable than having a large number of formulations that solve the same problem.
Company Developments Mapped to Drivers, Trends and Opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Danone completed its majority acquisition of Kate Farms in July 2025, expanding its specialized nutrition platform across hospital and home channels. | Patients often require continuing nutrition after leaving the treatment center. | Specialized nutrition companies are connecting institutional initiation with home replenishment. | Broader channel coverage can retain patients as their nutrition setting changes. |
| Medtrition launched ProSource Cup and ProSource Cup Plant in March 2025 with 20 g of complete protein in a low-volume serving. | Reduced appetite and treatment symptoms can make larger nutrition volumes difficult to consume. | Compact protein delivery is gaining relevance within medically supervised nutrition. | Low-volume formats can address patients who need additional protein without a full-size beverage. |
| B. Braun updated its Nutricomp Drink 2.0 kcals fibre catalog record in June 2026. | Disease-related malnutrition increases demand for calorie-dense nutrition in limited serving volumes. | Clinical nutrition portfolios are supporting multiple stages of nutritional escalation. | Suppliers can connect high-energy oral products with broader enteral-care capabilities. |
The competitive advantage is increasingly tied to how many stages of the patient's nutrition journey a supplier can cover without creating unnecessary changes in brand, product family, or purchasing route. That gives an edge to companies that combine appropriate formulations with hospital access and a workable way for patients to continue receiving nutrition after discharge.
Who leads the radiotherapy support nutrition market?
There is no single competitive model across this market. Nestlé Health Science, Danone Nutricia, and Abbott compete with broad medical nutrition portfolios. Fresenius Kabi and B. Braun are strong where clinical nutrition and enteral feeding are important. Medtrition, Victus, and Lyons Health Labs have more focused positions in areas such as concentrated protein, altered texture, and symptom-specific nutrition. Their relevance changes according to what the patient needs at a particular point in treatment.
Which suppliers can support oral-to-enteral nutrition pathways?
Fresenius Kabi, B. Braun, Danone Nutricia, Nestlé Health Science, and Abbott have portfolios that can support more than one feeding requirement. This matters when a patient who began with oral nutrition can no longer meet nutritional needs by mouth. Hospitals often prefer suppliers that can support this transition without forcing a complete change in the nutrition plan.
Which companies compete through concentrated or symptom-adapted nutrition?
Medtrition competes through compact protein products that can deliver substantial protein in a small serving. Lyons Health Labs participates in areas such as dysphagia and unintended weight loss, where texture and calorie density become important. Victus offers specialized clinical nutrition formulations aimed at more targeted nutrition needs. These companies can compete effectively when a focused product solves a problem that a general nutrition drink does not.
Which capabilities matter most to cancer-center buyers?
Cancer-center buyers need products that patients can actually use throughout treatment. Nutrient density matters, but so do serving volume, texture, preparation, tolerance, formulary availability, and access after discharge. The right combination changes with the radiation site, the severity of side effects, the stage of treatment, and whether the patient can continue eating orally.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Nestlé Health Science | Broad medical nutrition platform with oral and specialized nutrition capabilities across clinical settings. | In 2026, Nestlé highlighted the Onavida study of Meritene Clinical Extra Protein across 18 hospitals and more than 230 patients in Spain, examining high-protein oral nutritional support in cancer-related malnutrition. |
| Danone Nutricia | Specialized nutrition company with established hospital, oral nutrition, and homecare participation. | Danone completed its majority acquisition of Kate Farms in July 2025, strengthening specialized nutrition reach across hospital and home channels. |
| Abbott | Global clinical nutrition supplier with high-protein and calorie-dense oral nutrition products. | Abbott launched Ensure Strength Pro in India in May 2026, adding a 30 g high-protein adult nutrition product to its Ensure portfolio. |
| Fresenius Kabi | Clinical nutrition supplier with strong oral and enteral nutrition capabilities. | Fresenius Kabi launched Fresubin PLANT-BASED Drink in 2025 as a high-energy, high-protein oral nutritional supplement and expanded the range with a plant-based tube feed in March 2026. |
| Medtrition | Specialist in concentrated protein and medically supervised nutrition products. | Medtrition launched ProSource Cup and ProSource Cup Plant in March 2025. |
| B. Braun | Clinical nutrition company with oral and enteral feeding products integrated into hospital procurement channels. | On June 3, 2026, B. Braun updated its catalog record for Nutricomp Drink 2.0 kcals fibre, a high-energy medical nutrition product for disease-related malnutrition. |
Research Methodology
FMI evaluates the Radiotherapy Support Nutrition Market by looking at how nutrition products are actually used through the radiotherapy care pathway. The assessment considers differences by radiation site, treatment phase, feeding route, end user, and sales channel, along with the role of high-protein oral nutrition, enteral feeds, mucosal-support products, and texture-adapted formats.
Forecast assumptions reflect changes in radiotherapy activity, nutrition screening, treatment-related eating problems, movement from oral to enteral support, hospital purchasing, reimbursement, and use after discharge. Competitive analysis focuses on the products and channel capabilities that matter when nutrition has to be managed during or after radiotherapy.
